We Advance Cancer Research for Life-Changing Results

TRIO is a not-for-profit, full-service oncology CRO that leverages a unique blend of academic leaders, a global network of Investigators and a passionate, experienced team to accelerate the delivery of quality oncology trials.

We’ve spent decades conducting oncology trials from inception to completion, focusing on the best research and science to guide the development of innovative and biologically sound therapies. This translational research model allows us to bring targeted concepts into clinics on the most rational development path. We find the shortest course to save lives.

Services we offer

Our Services

TRIO is a full-service CRO that specializes in oncology. We primarily conduct phase I to phase III trials. Our services cover the entire clinical research spectrum—from study conception to design, execution, data analysis and results presentation.

Our World-class team

Our Team

Our team of world-class clinical research professionals works hard to optimize trial design and conduction, all while establishing and maintaining effective collaborations with our Sponsors and Investigators. Our Operations team has close connections with Key Opinion Leaders who are pivotal for the design and execution of clinical trials—trials that are making a difference.

TRIO - expert network of investigators

Our Investigator Network

We’re proud to have built a Top Tier Network comprised of 500 highly experienced, sought-after investigational sites in more than 20 countries on four continents.

Meet Our Leaders

Catherine Marle, MSc, PgD

Chief Executive Officer

Read Bio

Valérie Bee-Muntenau, MSc, MBA

Vice President, Project Management

Read Bio

Melanie Fauvel, PharmD

Senior Director, Quality Assurance

Read Bio

Rodrigo Fresco, MD

Vice President, Medical Affairs

Read Bio

Gavin Lyons, BComm

Vice President, Information Services

Read Bio

Véronique Moineau, MSc

Vice President, Monitoring Resources

Read Bio

Alexandra Neff, CPA, PMP

Chief Financial Officer

Read Bio

Christine Pangilinan, BSc, CPHR

Vice President, Human Resources

Read Bio

Matthieu Rupin, MSc

Vice President, Strategy and Clinical Collaborations

Read Bio

Directors

Dennis Slamon, MD, PhD

University of California, Los Angeles, USA

TRIO Chairman & Executive Director

Read Bio

Peter Fasching, MD

University Hospital of the Friedrich-Alexander, University Erlangen-Nuremberg, Germany

Read Bio

John Glaspy, MD, MPH

University of California, Los Angeles, USA

Read Bio

Seock-Ah Im, MD, PhD

Seoul National University, South Korea

Read Bio

Miguel Martin, MD, PhD

Hospital General Universitario Gregorio Marañón, Spain

Read Bio

Fran Visco

National Breast Cancer Coalition, USA

Read Bio

Officers

Catherine Marle, MSc, PgD

Chief Executive Officer

Read Bio

Alexandra Neff, CPA, PMP

Chief Financial Officer

Read Bio

Doug Goss, QC, AOE, LL.D.

TRIO Corporate Secretary and General Counsel

Read Bio

Dennis Slamon, MD, PhD

University of California, Los Angeles, USA

TRIO Chairman & Executive Director

Read Bio

Aditya Bardia, MD, MPH

University of California, Los Angeles, USA

Read Bio

John Crown, MD, MBA

St. Vincent's Hospital, Ireland

Read Bio

Peter Fasching, MD

University Hospital of the Friedrich-Alexander, University Erlangen-Nuremberg, Germany

Read Bio

Valentina Guarneri, MD, PhD

University of Padua, Italy

Read Bio

Sara Hurvitz, MD

University of Washington, USA

Read Bio

Jeeyun Lee, MD

Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

Read Bio

Yen Shen Lu, MD, PhD

National Taiwan University Hospital, Taiwan

Read Bio

Teresa Macarulla, MD, PhD

Vall d’Hebron University Hospital, Barcelona, Spain

Read Bio

Tadeusz Pienkowski, MD, PhD

The Cancer Center in Radom Cancer Center, Poland

Read Bio

Kohei Shitara, MD

National Cancer Center Hospital East, Kashiwa, Japan

Read Bio

Michelle Tregear, PhD

National Breast Cancer Coalition, USA

Read Bio

Vicente Valero, MD, FACP

The University of Texas MD Anderson Cancer Center, USA

Read Bio

Zev Wainberg, MD

University of California, Los Angeles, USA

TRIO GI Cancer Scientific Committee Chair

Read Bio

Our Story. Our Uniqueness.

TRIO was originally established in 1997 as BCIRG (Breast Cancer International Research Group), when we immediately contributed to establish docetaxel’s role in the treatment of early breast cancer, following the results of the BCIRG-001 trial.

In 1999, BCIRG changed its name to CIRG (Cancer International Research Group), reflecting the expanded range of cancer types in our trial portfolio. In this same year, we became one of the first groups to successfully establish a pre-randomization tumor tissue acquisition and central laboratory process, whereby patients’ tumor tissues were collected and evaluated centrally for a specific biomarker prior to entry into a clinical trial.

TRIO’s novel oncology clinical trials differ from many trials in that agent selection and study design are informed by rigorous preclinical evaluation performed by the group led by our Chairman of the Board, Dr. Dennis Slamon, at the Translational Oncology Research Laboratory (TORL) in the Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA).

To formalize our translational research model with TORL, our name was changed to Translational Research In Oncology (TRIO) in 2011. Throughout the years, we’ve contributed to drug development in oncology from First-in-human to registration trials. Among these trials, four have led to cancer drugs or regimens that have changed the practice of oncology—helping countless patients worldwide.

Practice Changing Trials

Clipboard icon

BCIRG001

Docetaxel in early breast cancer

Clipboard icon

BCIRG006

Trastuzumab in early breast cancer

Clipboard icon

TRIO018/TRIO022

Palbociclib in advanced breast cancer

Clipboard icon

TRIO023

Talazoparib in germline BRCA-mutated advanced breast cancer

TRIO US-SMO logo

TRIO-US SMO

TRIO-US SMO is our sister site management organization (SMO) in the US. It’s comprised of independent oncology practices across the country, providing cutting-edge cancer research and care to patients in their communities.

With the TRIO-US SMO site network, we’ve established efficiencies that allow us to expedite trial activation in the US. We can guarantee enrollment of the first patient within 100 days of the protocol package.

An Independent Not-For-Profit Organization

Our not-for-profit structure allows us to focus entirely on fulfilling our mission: to serve patients’ needs by conducting clinical trials that make a difference. This model:

  • Empowers us to choose our own direction
  • Allows us to operate with freedom from shareholder interests
  • Gives us the ability to reinvest our profit, so we can further develop our competencies and improve efficiencies that accelerate the development of successful anti-cancer agents and, ultimately, bring real change to the lives of patients with cancer

Values, Mission, and Value Proposition

VALUES: Innovation, teamwork, passion, integrity

MISSION: We aspire to change the lives of cancer patients by conducting clinical trials that make a difference

VALUE PROPOSITION: We’re a full-service oncology CRO that brings a unique blend of academic leaders, a global network of Investigators, and a passionate experienced team. We’re your partner for accelerated drug development.

Patient diversity in TRIO trials

At TRIO, we’re committed to creating change for the better. We do our part to nurture an inclusive future for clinical research and build trust within diverse communities. We’re committed to clinical trial enrollment that reflects the racial and ethnic diversity of the countries where our clinical trials are conducted, addressing both informational and practical barriers to clinical trial participation.

Ensuring diversity in clinical trials is a matter of equity. Everyone deserves a chance to raise their hand and participate, contribute, and ultimately benefit patients in their communities.

Environmental sustainability statement in operating model

As a focused clinical research organization, we recognize a link between our mission to support innovation in patients’ treatment and the need to have an environmental sustainability ambition in our operating model. We commit to keep this as a priority in all our activities to reduce our environmental footprint.